An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models

INTRODUCTION: The human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase (RTK) oncogene is an attractive therapeutic target for the treatment of HER2-addicted tumors. Although lapatinib, an FDA-approved small-molecule HER2 and epidermal growth factor receptor (EGFR) tyrosine kinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Wenle, Petricoin, Emanual F, Zhao, Sumin, Liu, Leihua, Osada, Takuya, Cheng, Qing, Wulfkuhle, Julia D, Gwin, William R, Yang, Xiaoyi, Gallagher, Rosa I, Bacus, Sarah, Lyerly, H Kim, Spector, Neil L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978995/
https://www.ncbi.nlm.nih.gov/pubmed/24044505
http://dx.doi.org/10.1186/bcr3480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978995/
https://www.ncbi.nlm.nih.gov/pubmed/24044505
http://dx.doi.org/10.1186/bcr3480

Ejemplares similares